Pfizer Inc.’s Centers for Therapeutic Innovation (CTI) announced a partnership on Nov. 7 with the non-profit Alliance for Lupus Research (ALR) to identify and co-fund the translation of promising lupus treatments into Phase I testing. The collaboration is the first in which a Big Pharma joins with academia and a non-profit research foundation to accelerate emerging science. As such, it’s a reminder of how the R&D ecosystem – its stakeholders, organizational structures, and incentives – is rapidly evolving from the only-within-our-walls mindset to a team-based approach.
It’s also an experiment in reconciling the skill sets, goals, and expectations of three very different players in life science...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?